Pfizer
PFE
S$32.82
Share price
1.51%
Change (1 day)
-13.00%
Change (1 year)
Categories
Pfizer Inc., is a global pharmaceutical company headquartered in New York City, New York, United States. It was founded by Charles Pfizer from Ludwigsburg. Pfizer is the second largest pharmaceutical company in the world after Roche, followed by Novartis.
Revenue for Pfizer (PFE)
Revenue in 2025 (TTM): S$83.31 Billion
According to Pfizer's latest financial reports the company's current revenue (TTM 
) is S$80.01 Billion. In 2024 the company made a revenue of S$86.48 Billion an increase over the revenue in the year 2023 that were of S$78.22 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pfizer from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | S$83.31 B | -3.67% |
| 2024 | S$86.48 B | 10.56% |
| 2023 | S$78.22 B | -41.84% |
| 2022 | S$134.50 B | 22.7% |
| 2021 | S$109.61 B | 129.08% |
| 2020 | S$47.85 B | -31.41% |
| 2019 | S$69.76 B | -4.8% |
| 2018 | S$73.28 B | 4.28% |
| 2017 | S$70.28 B | -8.07% |
| 2016 | S$76.45 B | 10.64% |
| 2015 | S$69.10 B | 5.43% |
| 2014 | S$65.54 B | 0.29% |
| 2013 | S$65.35 B | -6.03% |
| 2012 | S$69.55 B | -19.05% |
| 2011 | S$85.91 B | -0.84% |
| 2010 | S$86.64 B | 23.41% |
| 2009 | S$70.20 B | 1.65% |
| 2008 | S$69.06 B | -0.87% |
| 2007 | S$69.67 B | -6.07% |
| 2006 | S$74.17 B | -9.82% |
| 2005 | S$82.24 B | -4% |
| 2004 | S$85.67 B | 12.21% |
| 2003 | S$76.35 B | 45.54% |
| 2002 | S$52.46 B | -11.95% |
| 2001 | S$59.58 B | 16.87% |
| 2000 | S$50.97 B | 41.12% |
| 1999 | S$36.12 B | 61.55% |
| 1998 | S$22.36 B | 9.09% |
| 1997 | S$20.49 B | 29.55% |
| 1996 | S$15.82 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Merck MRK | S$81.88 B | 2.34% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$114.43 B | 43.01% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$61.02 B | -23.74% | 🇺🇸 USA |
 Eli Lilly LLY | S$62.77 B | -21.55% | 🇺🇸 USA |
 Novartis NVS | S$68.17 B | -14.79% | 🇨🇭 Switzerland |
 GlaxoSmithKline GSK | S$51.99 B | -35.02% | 🇬🇧 UK |
 Amgen AMGN | S$43.71 B | -45.37% | 🇺🇸 USA |
 Abbott Laboratories ABT | S$54.24 B | -32.21% | 🇺🇸 USA |
 AstraZeneca AZN | S$70.43 B | -11.98% | 🇬🇧 UK |